Picture of Pulmonx logo

LUNG Pulmonx News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMicro CapValue Trap

Pulmonx Corp expected to post a loss of 41 cents a share - Earnings Preview

* Pulmonx Corp  LUNG.OQ   LUNG.O  is expected to show a rise
in
quarterly revenue when it reports  results on February 21 for
the period ending December 31 2023
    * The Redwood City California-based  company is expected to
report
a 18.5% increase in revenue to $18.273 million from $15.43
million a year ago, according to the mean estimate from 5
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Pulmonx Corp is for a
loss
of 41 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pulmonx
Corp is
$15.00​, above​ its last closing price of $14.32. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.42       -0.43      -0.39     Beat    8.8
 Jun. 30 2023  -0.44       -0.44      -0.43     Beat    1.6
 Mar. 31 2023  -0.44       -0.44      -0.42     Beat    4.5​
 Dec. 31 2022  -0.43       -0.42      -0.38     Beat    8.7
 ​​Sep.        -0.40       -0.40      -0.38     Beat    4.2
 30 2022                                                
 Jun. 30 2022  -0.42       -0.41      -0.40     Beat    2.4​
 Mar. 31 2022  -0.38       -0.37      -0.43     Missed  -15.9
 Dec. 31 2021  -0.36       -0.36      -0.35     Beat    2.9
 This summary was machine generated February 19 at 21:33 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Pulmonx

See all news